J.P. Morgan Life Sciences Private Capital, a small team within the investment banking giant, has closed its inaugural life sciences fund, raising over $500 million. This fund will be invested in a wide range of private biotech companies, with a particular focus on the burgeoning field of weight-loss drugs. Steve Squinto played a key role in this first fundraising effort.
BIO CEO’s patriotic pivot; Step forward for Lilly’s Alzheimer’s drug; Pfizer’s gene therapy setback; Foresite’s $900M fund https://t.co/gvVxu8lTPV #biotech #news
Venture Report: Clinical plays Alzheon, Bright Peak raise growth capital. Early-stage financings for InduPro, Syntis and Moleculent. J.P. Morgan closes its life sciences vehicle, and SCI Ventures raises new fund for spinal injury https://t.co/IZFZ5oI9zI
News Roundup: Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing https://t.co/NtCq3DAE0R
JPMorgan to wager on weight-loss drug boom with $500M fund https://t.co/bR7nR2ZIqB
Epoch 24: Sweat Equity - Your Weekly Biotech News Fix Designed to be consumed as quick scroll with links to full length content if interested to dig deeper. 👉 $PFE and Flagship announce obesity collaboration 👉 Versant build "anger mgmt for the immune system" 👉 Secondary… https://t.co/wWDz7iopHN
J.P. Morgan Private Capital has closed an inaugural life sciences fund of more than $500 million, cash that will go toward a wide range of private biotechs. https://t.co/IUqdQpYKu3
Five takeaways from my convo w/ steve squinto as JP Morgan closes its first $500M biotech fund — https://t.co/7xwhP6bz73
J.P. Morgan Life Sciences Private Capital, a small team within the investment banking giant, closed its first fundraising, bringing in more than $500 million to invest in life science startups.… https://t.co/QeLHEdMltN
Epoch 24: Nothing is Easy in Biotech 👉 Macro update, not what you expect! 👉 Private biotech deal comp trends 👉 BIG news in from $LLY in Alzheimer's 👉 Pfizer's DMD fail & implications for $SRPT (l!nk to substa**ck in b!o) https://t.co/CDgg4stN63
JPMorgan raised more than $500 million for a biotech venture-capital fund that will bet on the hottest corner of health care: weight-loss drugs https://t.co/izAJAsnSt4
This week on "The Readout LOUD": A Duchenne gene therapy setback, an Alzheimer's drug endorsement, and why a STAT reporter buys weed (for journalism). https://t.co/9r8I1dyAwA